ArticleProceedings of the National Academy of Sciences of the United States of America2012
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed, 1 synthesis or guideline pooled it, 257 citations in OpenAlex.
- Partial protection against 2009 pandemic influenza A (H1N1) of seasonal influenza vaccination and related regional factors: Updated systematic review and meta-analyses.Human vaccines & immunotherapeutics · 2015Pooled it
- Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.Nature communications · 2019Trial
- High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine.The Journal of infectious diseases · 2015Trial
- Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.Human vaccines & immunotherapeutics · 2015Trial
- Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Humoral antibody response after receipt of inactivated seasonal influenza vaccinations one year apart in children.The Pediatric infectious disease journal · 2012Trial
- Subtype-specific neutralizing antibodies promote antigenic shift during influenza virus co-infection.Virulence · 2026Article
- Polyclonal breast milk-derived secretory IgA confers broad antiviral protection against multiple respiratory viruses.Science advances · 2026Article
- Counteracting Influenza Virus Evolution Through the Full Spectrum of Broadly Protective Antibodies.Immunological reviews · 2026Review
- Mucosal delivery of influenza antigens using a replication deficient adenovirus supports broadly reactive antibody responses and heterologous viral immunity in the respiratory tract of animals.bioRxiv : the preprint server for biology · 2025Article
- Preexisting immunity to the 2009 pandemic H1N1 virus reduces susceptibility to H5N1 infection and disease in ferrets.Science translational medicine · 2025Article
- Influenza A(H5N1) Immune Response among Ferrets with Influenza A(H1N1)pdm09 Immunity.Emerging infectious diseases · 2025Article
- How immunity shapes the long-term dynamics of influenza H3N2.PLoS computational biology · 2025Article
- Structural characterization of influenza group 1 chimeric hemagglutinins as broad vaccine immunogens.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Evolutionary dynamics and molecular epidemiology of H1N1 pandemic 2009 influenza A viruses across swine farms in Denmark.Virus evolution · 2025Article
- Pre-existing H1N1 immunity reduces severe disease with bovine H5N1 influenza virus.bioRxiv : the preprint server for biology · 2024Article
- Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.NPJ vaccines · 2024Article
- Generation of antigen-specific memory CD4 T cells by heterologous immunization enhances the magnitude of the germinal center response upon influenza infection.PLoS pathogens · 2024Article
- Structural basis for the broad antigenicity of the computationally optimized influenza hemagglutinin X6.Structure (London, England : 1993) · 2024Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 4 countries.
Funding
Abstract
After the emergence of pandemic influenza viruses in 1957, 1968, and 2009, existing seasonal viruses were observed to be replaced in the human population by the novel pandemic strains. We have previously hypothesized that the replacement of seasonal strains was mediated, in part, by a population-scale boost in antibodies specific for conserved regions of the hemagglutinin stalk and the viral neuraminidase. Numerous recent studies have shown the role of stalk-specific antibodies in neutralization of influenza viruses; the finding that stalk antibodies can effectively neutralize virus alters the existing dogma that influenza virus neutralization is mediated solely by antibodies that react with the globular head of the viral hemagglutinin. The present study explores the possibility that stalk-specific antibodies were boosted by infection with the 2009 H1N1 pandemic virus and that those antibodies could have contributed to the disappearance of existing seasonal H1N1 influenza virus strains. To study stalk-specific antibodies, we have developed chimeric hemagglutinin constructs that enable the measurement of antibodies that bind the hemagglutinin protein and neutralize virus but do not have hemagglutination inhibition activity. Using these chimeric hemagglutinin reagents, we show that infection with the 2009 pandemic H1N1 virus elicited a boost in titer of virus-neutralizing antibodies directed against the hemagglutinin stalk. In addition, we describe assays that can be used to measure influenza virus-neutralizing antibodies that are not detected in the traditional hemagglutination inhibition assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.